Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite (folate antagonist) presented as a subcutaneous formulation for injection use. It is employed to modify disease activity in autoimmune conditions and to treat certain cancers in adult and pediatric patients.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methofill is a folate‑antagonist used across several disease families, primarily autoimmune and oncologic disorders. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage in adult patients. - Psoriasis: improves skin lesions and decreases disease severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation as part of combination chemotherapy. - Osteosarcoma: contributes to tumor growth inhibition when used in multimodal regimens.

Methofill may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or malaise - Oral mucositis or ulceration - Elevated liver enzymes - Alopecia (hair loss) - Headache

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Pulmonary toxicity, including interstitial pneumonitis - Severe hepatotoxicity or fibrosis - Acute renal failure - Life‑threatening infections - Anaphylactic or severe hypersensitivity reactions

Before initiating Methofill, clinicians should assess baseline organ function and counsel patients on safety measures. - Monitor blood counts: perform complete blood count regularly to detect marrow suppression. - Assess liver function: check transaminases and bilirubin before and during therapy. - Evaluate renal function: adjust use in patients with impaired clearance. - Avoid use in pregnancy: drug is contraindicated and teratogenic. - Counsel on contraception: effective methods required for both sexes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Trimethoprim‑sulfamethoxazole: potentiates myelosuppression. - Proton pump inhibitors: may raise methotrexate levels. - Live vaccines: risk of severe infection. - Alcohol: exacerbates hepatotoxicity.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: additive bone‑marrow effects. - Cyclosporine: may increase methotrexate concentrations. - Sulfonamide antibiotics: enhance toxicity. - Penicillins: possible competitive renal excretion. - Warfarin: may augment anticoagulant effect.